Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.

Racioppi L, Nelson ER, Huang W, Mukherjee D, Lawrence SA, Lento W, Masci AM, Jiao Y, Park S, York B, Liu Y, Baek AE, Drewry DH, Zuercher WJ, Bertani FR, Businaro L, Geradts J, Hall A, Means AR, Chao N, Chang CY, McDonnell DP.

Nat Commun. 2019 Jun 4;10(1):2450. doi: 10.1038/s41467-019-10424-5.

2.

Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.

Chen EP, Markosyan N, Connolly E, Lawson JA, Li X, Grant GR, Grosser T, FitzGerald GA, Smyth EM.

Carcinogenesis. 2014 Aug;35(8):1788-97. doi: 10.1093/carcin/bgu053. Epub 2014 Mar 3.

3.

Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.

Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH, Smyth EM.

Breast Cancer Res. 2013;15(5):R75.

4.

Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells.

Hix LM, Karavitis J, Khan MW, Shi YH, Khazaie K, Zhang M.

J Biol Chem. 2013 Apr 26;288(17):11676-88. doi: 10.1074/jbc.M112.441402. Epub 2013 Mar 13.

5.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.

Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.

6.

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.

Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, Davidson NE, Huang Y.

Oncogene. 2019 Jan;38(3):390-405. doi: 10.1038/s41388-018-0451-5. Epub 2018 Aug 15.

7.

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.

Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, Rhim AD, Simeone DM, Beatty GL, Pasca di Magliano M.

Gut. 2017 Jan;66(1):124-136. doi: 10.1136/gutjnl-2016-312078. Epub 2016 Jul 8.

8.

Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.

Sanders KL, Fox BA, Bzik DJ.

Cancer Immunol Res. 2015 Aug;3(8):891-901. doi: 10.1158/2326-6066.CIR-14-0235. Epub 2015 Mar 24.

9.

Calcium/calmodulin-dependent protein kinase kinase 2 regulates macrophage-mediated inflammatory responses.

Racioppi L, Noeldner PK, Lin F, Arvai S, Means AR.

J Biol Chem. 2012 Mar 30;287(14):11579-91. doi: 10.1074/jbc.M111.336032. Epub 2012 Feb 14.

10.

Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.

Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, Liu X, Deering T, Avella DM, Fox T, Rockey DC, Schell TD, Kester M, Staveley-O'Carroll KF.

Gastroenterology. 2018 Mar;154(4):1024-1036.e9. doi: 10.1053/j.gastro.2017.10.050. Epub 2018 Jan 31.

11.

Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.

Gocher AM, Azabdaftari G, Euscher LM, Dai S, Karacosta LG, Franke TF, Edelman AM.

J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.

12.

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.

Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S.

Nat Commun. 2017 Sep 19;8(1):606. doi: 10.1038/s41467-017-00728-9.

13.

Inhibition of Ca²⁺/calmodulin-dependent protein kinase kinase 2 stimulates osteoblast formation and inhibits osteoclast differentiation.

Cary RL, Waddell S, Racioppi L, Long F, Novack DV, Voor MJ, Sankar U.

J Bone Miner Res. 2013 Jul;28(7):1599-610. doi: 10.1002/jbmr.1890.

14.

The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.

Duechler M, Peczek L, Zuk K, Zalesna I, Jeziorski A, Czyz M.

Immunobiology. 2014 Feb;219(2):158-65. doi: 10.1016/j.imbio.2013.09.003. Epub 2013 Sep 8.

PMID:
24091277
15.

A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.

Karacosta LG, Foster BA, Azabdaftari G, Feliciano DM, Edelman AM.

J Biol Chem. 2012 Jul 13;287(29):24832-43. doi: 10.1074/jbc.M112.370783. Epub 2012 May 31.

16.

Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.

Cekic C, Day YJ, Sag D, Linden J.

Cancer Res. 2014 Dec 15;74(24):7250-9. doi: 10.1158/0008-5472.CAN-13-3583. Epub 2014 Nov 6.

17.

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.

Khan AN, Kolomeyevskaya N, Singel KL, Grimm MJ, Moysich KB, Daudi S, Grzankowski KS, Lele S, Ylagan L, Webster GA, Abrams SI, Odunsi K, Segal BH.

Oncotarget. 2015 May 10;6(13):11310-26.

18.

Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models.

Gad E, Rastetter L, Slota M, Koehnlein M, Treuting PM, Dang Y, Stanton S, Disis ML.

Breast Cancer Res Treat. 2014 Dec;148(3):501-10. doi: 10.1007/s10549-014-3199-9. Epub 2014 Nov 14.

19.

GADD45β Loss Ablates Innate Immunosuppression in Cancer.

Verzella D, Bennett J, Fischietti M, Thotakura AK, Recordati C, Pasqualini F, Capece D, Vecchiotti D, D'Andrea D, Di Francesco B, De Maglie M, Begalli F, Tornatore L, Papa S, Lawrence T, Forbes SJ, Sica A, Alesse E, Zazzeroni F, Franzoso G.

Cancer Res. 2018 Mar 1;78(5):1275-1292. doi: 10.1158/0008-5472.CAN-17-1833. Epub 2017 Dec 26.

20.

Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.

Barakat DJ, Suresh R, Barberi T, Pienta KJ, Simons BW, Friedman AD.

PLoS One. 2018 Jan 11;13(1):e0191188. doi: 10.1371/journal.pone.0191188. eCollection 2018.

Supplemental Content

Support Center